RU2752497C2 - Улучшенные последовательности уриказы и способы лечения - Google Patents

Улучшенные последовательности уриказы и способы лечения Download PDF

Info

Publication number
RU2752497C2
RU2752497C2 RU2017143580A RU2017143580A RU2752497C2 RU 2752497 C2 RU2752497 C2 RU 2752497C2 RU 2017143580 A RU2017143580 A RU 2017143580A RU 2017143580 A RU2017143580 A RU 2017143580A RU 2752497 C2 RU2752497 C2 RU 2752497C2
Authority
RU
Russia
Prior art keywords
uricase
amino acid
seq
peg
xaa
Prior art date
Application number
RU2017143580A
Other languages
English (en)
Russian (ru)
Other versions
RU2017143580A3 (enExample
RU2017143580A (ru
Inventor
Мануэль БАКА
Эндрю К. НАЙБОРГ
Original Assignee
МЕДИММЬЮН, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МЕДИММЬЮН, ЭлЭлСи filed Critical МЕДИММЬЮН, ЭлЭлСи
Publication of RU2017143580A publication Critical patent/RU2017143580A/ru
Publication of RU2017143580A3 publication Critical patent/RU2017143580A3/ru
Application granted granted Critical
Publication of RU2752497C2 publication Critical patent/RU2752497C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2017143580A 2015-05-15 2016-05-13 Улучшенные последовательности уриказы и способы лечения RU2752497C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562162280P 2015-05-15 2015-05-15
US62/162,280 2015-05-15
PCT/US2016/032415 WO2016187026A1 (en) 2015-05-15 2016-05-13 Improved uricase sequences and methods of treatment

Publications (3)

Publication Number Publication Date
RU2017143580A RU2017143580A (ru) 2019-06-17
RU2017143580A3 RU2017143580A3 (enExample) 2019-12-16
RU2752497C2 true RU2752497C2 (ru) 2021-07-28

Family

ID=57320301

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017143580A RU2752497C2 (ru) 2015-05-15 2016-05-13 Улучшенные последовательности уриказы и способы лечения

Country Status (18)

Country Link
US (3) US11098289B2 (enExample)
EP (1) EP3294322A4 (enExample)
JP (2) JP2018515101A (enExample)
KR (1) KR20180002828A (enExample)
CN (1) CN107614007B (enExample)
AU (2) AU2016265677B2 (enExample)
BR (1) BR112017024212A2 (enExample)
CA (1) CA2984926A1 (enExample)
CL (1) CL2017002774A1 (enExample)
CO (1) CO2017012454A2 (enExample)
HK (1) HK1252542A1 (enExample)
IL (1) IL255403A0 (enExample)
MX (1) MX2017014547A (enExample)
MY (1) MY190411A (enExample)
RU (1) RU2752497C2 (enExample)
SG (2) SG11201708759YA (enExample)
WO (1) WO2016187026A1 (enExample)
ZA (1) ZA201708507B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187026A1 (en) 2015-05-15 2016-11-24 Medimmune, Llc Improved uricase sequences and methods of treatment
CN106554948B (zh) * 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
CN112410313A (zh) * 2019-08-20 2021-02-26 中国科学院上海药物研究所 一种高热稳定性尿酸酶及其应用
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
CN114746546B (zh) * 2019-10-29 2024-09-03 西湖生物医药科技(杭州)有限公司 工程化红细胞用于治疗痛风和高尿酸血症
KR20230059777A (ko) 2020-09-25 2023-05-03 주식회사 프로앱텍 요산산화효소-알부민 접합체, 그 제조방법 및 용도
US20230374471A1 (en) * 2020-10-13 2023-11-23 University Of Florida Research Foundation, Incorporated Self-assembling uricase fusion peptides
JP7833461B2 (ja) 2020-11-03 2026-03-19 プロタリクス リミテッド 修飾ウリカーゼ及びその使用
CN114438048B (zh) * 2020-11-05 2024-10-22 重庆派金生物科技有限公司 尿酸氧化酶制剂及其应用
WO2022214086A1 (zh) * 2021-04-09 2022-10-13 上海君实生物医药科技股份有限公司 尿酸酶、其药物组合物及其用途
WO2023282556A1 (ko) * 2021-07-08 2023-01-12 주식회사 프로앱텍 Arthrobacter globiformis 유래 요산산화효소-알부민 접합체, 그 제조방법 및 그 용도
KR20240083169A (ko) * 2021-09-23 2024-06-11 주식회사 프로앱텍 Apn 그룹을 포함하는 링커 및 이를 이용하여 제조된 기능성 폴리펩티드 변이체-알부민 컨쥬게이트
US20250241999A1 (en) * 2021-10-15 2025-07-31 Georgia State University Research Foundation, Inc. Delivery of therapeutic recombinant uricase using nanoparticles
US12703857B2 (en) 2023-02-02 2026-08-11 Protalix Ltd. Methods of treating diseases associated with elevated uric acid
WO2026102031A1 (en) * 2024-11-06 2026-05-15 Insmed Incorporated Pasylated uricase variants and methods of use thereof
CN119752761B (zh) * 2025-03-07 2025-06-17 北京化工大学 一种高产heparosan的基因工程菌及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2435847C2 (ru) * 2005-04-11 2011-12-10 Савиент Фармасьютикалз, Инк. Вариантная форма урат-оксидазы и ее использование
US20130305398A1 (en) * 2012-02-16 2013-11-14 Marie Coffin Genes and uses for plant enhacement

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09154581A (ja) * 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
PL202799B1 (pl) 1998-08-06 2009-07-31 Mountain View Pharmaceuticals Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
ATE298251T1 (de) * 1998-08-06 2005-07-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US7056713B1 (en) 1998-08-06 2006-06-06 Duke University Urate oxidase
AU775937B2 (en) * 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
KR20080009111A (ko) * 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
ES2716864T3 (es) 2007-06-06 2019-06-17 Monsanto Technology Llc Genes y usos para la mejora de plantas
JP2012531596A (ja) 2009-06-25 2012-12-10 サヴィエント・ファーマシューティカルズ・インコーポレイテッド Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット
CN103184209B (zh) * 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
WO2016187026A1 (en) 2015-05-15 2016-11-24 Medimmune, Llc Improved uricase sequences and methods of treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2435847C2 (ru) * 2005-04-11 2011-12-10 Савиент Фармасьютикалз, Инк. Вариантная форма урат-оксидазы и ее использование
US20130305398A1 (en) * 2012-02-16 2013-11-14 Marie Coffin Genes and uses for plant enhacement

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Database UniProtKB / Swiss-Prot: D0VWQ1.1, 01.04.2015 Found on the Internet at https://www.ncbi.nlm.nih.gov/protein/327488515?sat=21&satkey=23772744. *
Database UniProtKB/Swiss-Prot: D0VWQ1.1, 01.04.2015 Найдено в интернет по адресу https://www.ncbi.nlm.nih.gov/protein/327488515?sat=21&satkey=23772744. *
SUZUKI K et.al Molecular cloning and expression of uricase gene from Arthrobacter globiformis in Escherichia coli and characterization of the gene product, J Biosci Bioeng. 2004;98(3):153-8.doi: 10.1016/S1389-1723(04)00259-2. *

Also Published As

Publication number Publication date
US11098289B2 (en) 2021-08-24
US10883087B2 (en) 2021-01-05
HK1252542A1 (zh) 2019-05-31
CL2017002774A1 (es) 2018-04-06
MY190411A (en) 2022-04-21
AU2016265677B2 (en) 2021-12-09
EP3294322A1 (en) 2018-03-21
JP2021184733A (ja) 2021-12-09
AU2016265677A1 (en) 2018-01-04
JP2018515101A (ja) 2018-06-14
RU2017143580A3 (enExample) 2019-12-16
US20190048327A1 (en) 2019-02-14
SG11201708759YA (en) 2017-11-29
CA2984926A1 (en) 2016-11-24
CN107614007B (zh) 2022-03-25
US20180258406A1 (en) 2018-09-13
IL255403A0 (en) 2017-12-31
SG10201910522TA (en) 2020-01-30
WO2016187026A1 (en) 2016-11-24
BR112017024212A2 (pt) 2018-07-17
AU2022200104A1 (en) 2022-02-03
CO2017012454A2 (es) 2018-04-30
MX2017014547A (es) 2018-03-15
CN107614007A (zh) 2018-01-19
KR20180002828A (ko) 2018-01-08
US20210254024A1 (en) 2021-08-19
EP3294322A4 (en) 2018-12-12
RU2017143580A (ru) 2019-06-17
ZA201708507B (en) 2018-11-28

Similar Documents

Publication Publication Date Title
US10883087B2 (en) Uricase sequences and methods of treatment
US10898545B2 (en) Tear lipocalin muteins binding IL-4 r alpha
KR20080007360A (ko) 유레이트 옥시다아제의 변이형 및 이의 용도
AU2020362820A1 (en) Improved uricase and method for treating hyperuricemia using same
Dolezal et al. Frataxin, a conserved mitochondrial protein, in the hydrogenosome of Trichomonas vaginalis
AU2023390556A1 (en) Uricase conjugates and methods of use thereof
WO2024233365A2 (en) Uricase variants and methods of use thereof
CN110603324A (zh) 用于治疗高同型半胱氨酸血症和同型胱胺酸尿症患者的人类酶介导的同型半胱氨酸耗竭
WO2021159205A1 (en) Chondroitinase abc mutants and methods of manufacture and use thereof
WO2026102031A1 (en) Pasylated uricase variants and methods of use thereof
WO2026102038A1 (en) Uricase variants and methods of use thereof
EP4705436A2 (en) Novel uricase variants and methods of use thereof
Dias Development of phenylalanine hydroxylase enzymosomes for the treatment of phenylketonuria
HK40016122A (en) Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria